Search

Your search keyword '"Funt, Samuel A."' showing total 395 results
Start Over Author "Funt, Samuel A."
395 results on '"Funt, Samuel A."'

1. Goal-Focused Emotion-Regulation Therapy (GET) in Young Adult Testicular Cancer Survivors: A Randomized Pilot Study

Author

Hoyt, Michael A, Wang, Ashley Wei-Ting, Ceja, Raymond Carrillo, Cheavens, Jennifer S, Daneshvar, Michael A, Feldman, Darren R, Funt, Samuel A, and Nelson, Christian J

Subjects
Clinical and Health Psychology, Health Services and Systems, Nursing, Health Sciences, Psychology, Cancer, Clinical Trials and Supportive Activities, Depression, Behavioral and Social Science, Women's Health, Mind and Body, Urologic Diseases, Pediatric, Mental Health, Clinical Research, Rare Diseases, Health Disparities, Brain Disorders, Mental Illness, Rehabilitation, 6.6 Psychological and behavioural, Male, Humans, Young Adult, Testicular Neoplasms, Pilot Projects, Emotional Regulation, Goals, Survivors, Testicular cancer, Emotion regulation, Young adults, Psycho-oncology, Survivorship, Biobehavioral, Medical and Health Sciences, Education, Psychology and Cognitive Sciences, Public Health, Health sciences
Abstract

BackgroundYoung adult testicular cancer survivors experience adverse impacts after treatment. We developed Goal-focused Emotion-regulation Therapy (GET) to improve distress symptoms, emotion regulation, and goal navigation skills.PurposeThis pilot study examined GET versus an active control intervention in young adult survivors of testicular cancer.MethodsSeventy-five eligible survivors treated with chemotherapy were randomized to receive GET or Individual Supportive Listening (ISL). Study acceptability, engagement, and tolerability were examined, and intervention fidelity and therapeutic alliance were compared between arms. Preliminary efficacy was evaluated by effect sizes for between-group changes in primary (anxiety and depressive symptoms) and secondary (career confusion, goal navigation, and emotion regulation) outcomes from baseline to immediately and 3-month post-intervention.ResultsAmong the 38 men randomized to GET, 81.1% completed all study sessions compared with 82.4% of the 37 men assigned to ISL. Fidelity to the intervention was 87% in GET. Therapeutic alliance wassignificantly higher among those receiving GET versus ISL. Participants exhibited a medium group-by-time effect size with greater reductions in depressive (d = 0.45) and anxiety (d = 0.29) symptoms for those in GET versus ISL, with a similar pattern at 3 months for depressive (d = 0.46) and anxiety (d = 0.46) symptoms.ConclusionsGET is a feasible and acceptable intervention for reducing adverse outcomes after testicular cancer for young adults. Observed effect sizes preliminarily suggest meaningful change, though should be interpreted with caution in small samples. GET may be a developmentally-matched behavioral approach to improve psychosocial function in this cancer group.Clinical trial informationClinicaltrials.gov, NCT04150848. Registered on October 28, 2019.

Published
2023

4. Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer

Author

Lenis, Andrew T., Whiting, Karissa, Ravichandran, Vignesh, Tallman, Jacob E., Alam, Syed M., Chu, Carissa E., Jesus Escano, Manual De, Bochner, Emily, Katims, Andrew, Reisz, Peter A., Truong, Hong, Clinton, Timothy N., Telis, Leon, Dason, Shawn, McPherson, Victor, Teo, Min Yuen, Funt, Samuel, Aggen, David, Goh, Alvin C., Donahue, Timothy F., Cha, Eugene K., Donat, S. Machele, Herr, Harry W., Dalbagni, Guido, Schultz, Nikolaus, Berger, Michael F., Bajorin, Dean F., Rosenberg, Jonathan E., Bochner, Bernard H., Ostrovnaya, Irina, Al-Ahmadie, Hikmat, Solit, David B., Iyer, Gopa, and Pietzak, Eugene J.

Published
2024
Full Text
View/download PDF

7. Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management

Author

Liu, Ying L., Manning-Geist, Beryl L., Knezevic, Andrea, Deng, Luxue, Bromberg, Maria, Funt, Samuel A., Meisel, Jane L., Zivanovic, Oliver, Long Roche, Kara, Sonoda, Yukio, Gardner, Ginger J., Grisham, Rachel N., O'Cearbhaill, Roisin E., Tew, William P., Abu-Rustum, Nadeem R., Chi, Dennis S., Aghajanian, Carol, and Feldman, Darren R.

Published
2023
Full Text
View/download PDF

10. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

Author

Herati, Ramin Sedaghat, Knorr, David A., Vella, Laura A., Silva, Luisa Victoria, Chilukuri, Lakshmi, Apostolidis, Sokratis A., Huang, Alexander C., Muselman, Alexander, Manne, Sasikanth, Kuthuru, Oliva, Staupe, Ryan P., Adamski, Sharon A., Kannan, Senthil, Kurupati, Raj K., Ertl, Hildegund C. J., Wong, Jeffrey L., Bournazos, Stylianos, McGettigan, Suzanne, Schuchter, Lynn M., Kotecha, Ritesh R., Funt, Samuel A., Voss, Martin H., Motzer, Robert J., Lee, Chung-Han, Bajorin, Dean F., Mitchell, Tara C., Ravetch, Jeffrey V., and Wherry, E. John

Published
2022
Full Text
View/download PDF

11. Fundamental immune–oncogenicity trade-offs define driver mutation fitness

Author

Hoyos, David, Zappasodi, Roberta, Schulze, Isabell, Sethna, Zachary, de Andrade, Kelvin César, Bajorin, Dean F., Bandlamudi, Chaitanya, Callahan, Margaret K., Funt, Samuel A., Hadrup, Sine R., Holm, Jeppe S., Rosenberg, Jonathan E., Shah, Sohrab P., Vázquez-García, Ignacio, Weigelt, Britta, Wu, Michelle, Zamarin, Dmitriy, Campitelli, Laura F., Osborne, Edward J., Klinger, Mark, Robins, Harlan S., Khincha, Payal P., Savage, Sharon A., Balachandran, Vinod P., Wolchok, Jedd D., Hellmann, Matthew D., Merghoub, Taha, Levine, Arnold J., Łuksza, Marta, and Greenbaum, Benjamin D.

Published
2022
Full Text
View/download PDF

12. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy

Author

Teo, Min Yuen, Guercio, Brendan J., Arora, Arshi, Hao, Xueli, Regazzi, Ashley M., Donahue, Timothy, Herr, Harry W., Goh, Alvin C., Cha, Eugene K., Pietzak, Eugene, Donat, Sherri M., Dalbagni, Guido, Bochner, Bernard H., Olgac, Semra, Sarungbam, Judy, Sirintrapun, S. Joseph, Chen, Ying-Bei, Gopalan, Anuradha, Fine, Samson W., Tickoo, Satish K., Reuter, Victor E., Weigelt, Britta, Schultheis, Anne M., Funt, Samuel A., Bajorin, Dean F., Solit, David B., Iyer, Gopa, Ostrovnaya, Irina, Rosenberg, Jonathan E., and Al-Ahmadie, Hikmat

Published
2022
Full Text
View/download PDF

13. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

Author

Holm, Jeppe Sejerø, Funt, Samuel A., Borch, Annie, Munk, Kamilla Kjærgaard, Bjerregaard, Anne-Mette, Reading, James L., Maher, Colleen, Regazzi, Ashley, Wong, Phillip, Al-Ahmadie, Hikmat, Iyer, Gopa, Tamhane, Tripti, Bentzen, Amalie Kai, Herschend, Nana Overgaard, De Wolf, Susan, Snyder, Alexandra, Merghoub, Taha, Wolchok, Jedd D., Nielsen, Morten, Rosenberg, Jonathan E., Bajorin, Dean F., and Hadrup, Sine Reker

Published
2022
Full Text
View/download PDF

14. Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation

Author

Warrick, Joshua I., Hu, Wenhuo, Yamashita, Hironobu, Walter, Vonn, Shuman, Lauren, Craig, Jenna M., Gellert, Lan L., Castro, Mauro A. A., Robertson, A. Gordon, Kuo, Fengshen, Ostrovnaya, Irina, Sarungbam, Judy, Chen, Ying-bei, Gopalan, Anuradha, Sirintrapun, Sahussapont J., Fine, Samson W., Tickoo, Satish K., Kim, Kwanghee, Thomas, Jasmine, Karan, Nagar, Gao, Sizhi Paul, Clinton, Timothy N., Lenis, Andrew T., Chan, Timothy A., Chen, Ziyu, Rao, Manisha, Hollman, Travis J., Li, Yanyun, Socci, Nicholas D., Chavan, Shweta, Viale, Agnes, Mohibullah, Neeman, Bochner, Bernard H., Pietzak, Eugene J., Teo, Min Yuen, Iyer, Gopa, Rosenberg, Jonathan E., Bajorin, Dean F., Kaag, Matthew, Merrill, Suzanne B., Joshi, Monika, Adam, Rosalyn, Taylor, III, John A., Clark, Peter E., Raman, Jay D., Reuter, Victor E., Chen, Yu, Funt, Samuel A., Solit, David B., DeGraff, David J., and Al-Ahmadie, Hikmat A.

Published
2022
Full Text
View/download PDF

15. FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation

Author

Warrick, Joshua I., Hu, Wenhuo, Yamashita, Hironobu, Walter, Vonn, Shuman, Lauren, Craig, Jenna M., Gellert, Lan L., Castro, Mauro A. A., Robertson, A. Gordon, Kuo, Fengshen, Ostrovnaya, Irina, Sarungbam, Judy, Chen, Ying-bei, Gopalan, Anuradha, Sirintrapun, Sahussapont J., Fine, Samson W., Tickoo, Satish K., Kim, Kwanghee, Thomas, Jasmine, Karan, Nagar, Gao, Sizhi Paul, Clinton, Timothy N., Lenis, Andrew T., Chan, Timothy A., Chen, Ziyu, Rao, Manisha, Hollman, Travis J., Li, Yanyun, Socci, Nicholas D., Chavan, Shweta, Viale, Agnes, Mohibullah, Neeman, Bochner, Bernard H., Pietzak, Eugene J., Teo, Min Yuen, Iyer, Gopa, Rosenberg, Jonathan E., Bajorin, Dean F., Kaag, Matthew, Merrill, Suzanne B., Joshi, Monika, Adam, Rosalyn, Taylor, III, John A., Clark, Peter E., Raman, Jay D., Reuter, Victor E., Chen, Yu, Funt, Samuel A., Solit, David B., DeGraff, David J., and Al-Ahmadie, Hikmat A.

Published
2022
Full Text
View/download PDF

18. A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor.

Author

Leiserson, Mark DM, Syrgkanis, Vasilis, Gilson, Amy, Dudik, Miroslav, Gillett, Sharon, Chayes, Jennifer, Borgs, Christian, Bajorin, Dean F, Rosenberg, Jonathan E, Funt, Samuel, Snyder, Alexandra, and Mackey, Lester

Subjects
T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Humans, Carcinoma, Transitional Cell, Antibodies, Monoclonal, Protein Kinase Inhibitors, Treatment Outcome, Immunotherapy, Models, Statistical, Risk Assessment, Cell Proliferation, Mutation, Adult, Female, Male, Urinary Bladder Neoplasms, Biomarkers, Pharmacological, Antibodies, Monoclonal, Humanized, Clonal Evolution, Biomarkers, Tumor, B7-H1 Antigen, Antibodies, Monoclonal, Humanized, Biomarkers, Pharmacological, Tumor, Carcinoma, Transitional Cell, Lymphocytes, Tumor-Infiltrating, Models, Statistical, General Science & Technology
Abstract

Checkpoint inhibitor immunotherapies have had major success in treating patients with late-stage cancers, yet the minority of patients benefit. Mutation load and PD-L1 staining are leading biomarkers associated with response, but each is an imperfect predictor. A key challenge to predicting response is modeling the interaction between the tumor and immune system. We begin to address this challenge with a multifactorial model for response to anti-PD-L1 therapy. We train a model to predict immune response in patients after treatment based on 36 clinical, tumor, and circulating features collected prior to treatment. We analyze data from 21 bladder cancer patients using the elastic net high-dimensional regression procedure and, as training set error is a biased and overly optimistic measure of prediction error, we use leave-one-out cross-validation to obtain unbiased estimates of accuracy on held-out patients. In held-out patients, the model explains 79% of the variance in T cell clonal expansion. This predicted immune response is multifactorial, as the variance explained is at most 23% if clinical, tumor, or circulating features are excluded. Moreover, if patients are triaged according to predicted expansion, only 38% of non-durable clinical benefit (DCB) patients need be treated to ensure that 100% of DCB patients are treated. In contrast, using mutation load or PD-L1 staining alone, one must treat at least 77% of non-DCB patients to ensure that all DCB patients receive treatment. Thus, integrative models of immune response may improve our ability to anticipate clinical benefit of immunotherapy.

Published
2018

21. IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition

Author

Borch, Annie, primary, Carri, Ibel, additional, Reynisson, Birkir, additional, Alvarez, Heli M. Garcia, additional, Munk, Kamilla K., additional, Montemurro, Alessandro, additional, Kristensen, Nikolaj Pagh, additional, Tvingsholm, Siri A., additional, Holm, Jeppe Sejerø, additional, Heeke, Christina, additional, Moss, Keith Henry, additional, Hansen, Ulla Kring, additional, Schaap-Johansen, Anna-Lisa, additional, Bagger, Frederik Otzen, additional, de Lima, Vinicius Araujo Barbosa, additional, Rohrberg, Kristoffer S., additional, Funt, Samuel A., additional, Donia, Marco, additional, Svane, Inge Marie, additional, Lassen, Ulrik, additional, Barra, Carolina, additional, Nielsen, Morten, additional, and Hadrup, Sine Reker, additional

Published
2024
Full Text
View/download PDF

22. IMPROVE:a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition

Author

Borch, Annie, Carri, Ibel, Reynisson, Birkir, Alvarez, Heli M.Garcia, Munk, Kamilla K., Montemurro, Alessandro, Kristensen, Nikolaj Pagh, Tvingsholm, Siri A., Holm, Jeppe Sejerø, Heeke, Christina, Moss, Keith Henry, Hansen, Ulla Kring, Schaap-Johansen, Anna Lisa, Bagger, Frederik Otzen, de Lima, Vinicius Araujo Barbosa, Rohrberg, Kristoffer S., Funt, Samuel A., Donia, Marco, Svane, Inge Marie, Lassen, Ulrik, Barra, Carolina, Nielsen, Morten, Hadrup, Sine Reker, Borch, Annie, Carri, Ibel, Reynisson, Birkir, Alvarez, Heli M.Garcia, Munk, Kamilla K., Montemurro, Alessandro, Kristensen, Nikolaj Pagh, Tvingsholm, Siri A., Holm, Jeppe Sejerø, Heeke, Christina, Moss, Keith Henry, Hansen, Ulla Kring, Schaap-Johansen, Anna Lisa, Bagger, Frederik Otzen, de Lima, Vinicius Araujo Barbosa, Rohrberg, Kristoffer S., Funt, Samuel A., Donia, Marco, Svane, Inge Marie, Lassen, Ulrik, Barra, Carolina, Nielsen, Morten, and Hadrup, Sine Reker

Abstract

Background: Mutation-derived neoantigens are critical targets for tumor rejection in cancer immunotherapy, and better tools for neoepitope identification and prediction are needed to improve neoepitope targeting strategies. Computational tools have enabled the identification of patient-specific neoantigen candidates from sequencing data, but limited data availability has hindered their capacity to predict which of the many neoepitopes will most likely give rise to T cell recognition. Method: To address this, we make use of experimentally validated T cell recognition towards 17,500 neoepitope candidates, with 467 being T cell recognized, across 70 cancer patients undergoing immunotherapy. Results: We evaluated 27 neoepitope characteristics, and created a random forest model, IMPROVE, to predict neoepitope immunogenicity. The presence of hydrophobic and aromatic residues in the peptide binding core were the most important features for predicting neoepitope immunogenicity. Conclusion: Overall, IMPROVE was found to significantly advance the identification of neoepitopes compared to other current methods.

Published
2024

23. Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

Author

Teo, Min Yuen, Al-Ahmadie, Hikmat, Seier, Kenneth, Tully, Christopher, Regazzi, Ashley M., Pietzak, Eugene, Solit, David B., Tickoo, Satish, Reuter, Victor, Cha, Eugene K., Herr, Harry, Donahue, Timothy, Donat, Sherri M., Dalbagni, Guido, Bochner, Bernard H., Funt, Samuel, Iyer, Gopakumar V., Bajorin, Dean F., Ostrovnaya, Irina, and Rosenberg, Jonathan E.

Published
2021
Full Text
View/download PDF

24. Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype

Author

Almassi, Nima, Whiting, Karissa, Toubaji, Antoun, Lenis, Andrew T., Jordan, Emmet J., Won, Helen, Regazzi, Ashley M., Chen, Ying-Bei, Gopalan, Anuradha, Sirintrapun, Sahussapont J., Fine, Samson W., Tickoo, Satish K., Ostrovnaya, Irina, Pietzak, Eugene J., Cha, Eugene K., Goh, Alvin C., Donahue, Timothy F., Herr, Harry W., Donat, S. Machele, Dalbagni, Guido, Bochner, Bernard H., Teo, Min Yuen, Funt, Samuel A., Rosenberg, Jonathan E., Reuter, Victor E., Bajorin, Dean F., Solit, David B., Al-Ahmadie, Hikmat, and Iyer, Gopa

Published
2022
Full Text
View/download PDF

25. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor

Author

Taylor, Justin, Donoghue, Mark T.A., Ho, Caleb, Petrova-Drus, Kseniya, Al-Ahmadie, Hikmat A., Funt, Samuel A., Zhang, Yanming, Aypar, Umut, Rao, Pavitra, Chavan, Shweta S., Haddadin, Michael, Tamari, Roni, Giralt, Sergio, Tallman, Martin S., Rampal, Raajit K., Baez, Priscilla, Kappagantula, Rajya, Kosuri, Satyajit, Dogan, Ahmet, Tickoo, Satish K., Reuter, Victor E., Bosl, George J., Iacobuzio-Donahue, Christine A., Solit, David B., Taylor, Barry S., Feldman, Darren R., and Abdel-Wahab, Omar

Subjects
Genotypes -- Identification and classification -- Health aspects, Germinoma -- Genetic aspects -- Development and progression -- Care and treatment, Gene mutation -- Health aspects, Gene expression -- Health aspects, Health care industry
Abstract

Germ cell tumors (GCTs) are the most common cancer in men between the ages of 15 and 40. Although most patients are cured, those with disease arising in the mediastinum have distinctly poor outcomes. One in every 17 patients with primary mediastinal nonseminomatous GCTs develop an incurable hematologic malignancy and prior data intriguingly suggest a clonal relationship exists between hematologic malignancies and GCTs in these cases. To date, however, the precise clonal relationship between GCTs and the diverse additional somatic malignancies arising in such individuals have not been determined. Here, we traced the clonal evolution and characterized the genetic features of each neoplasm from a cohort of 15 patients with GCTs and associated hematologic malignancies. We discovered that GCTs and hematologic malignancies developing in such individuals evolved from a common shared precursor, nearly all of which harbored allelically imbalanced p53 and/or RAS pathway mutations. Hematologic malignancies arising in this setting genetically resembled mediastinal GCTs rather than de novo myeloid neoplasms. Our findings argue that this scenario represents a unique clinical syndrome, distinct from de novo GCTs or hematologic malignancies, initiated by an ancestral precursor that gives rise to the parallel evolution of GCTs and blood cancers in these patients., Introduction Germ cell tumors (GCTs) are a model of curable cancer, as most patients with metastatic GCTs are successfully treated with cisplatin-based chemotherapy (1). However, up to 30% of patients [...]

Published
2020
Full Text
View/download PDF

26. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

Author

Tsui, Dana W. Y., Cheng, Michael L., Shady, Maha, Yang, Julie L., Stephens, Dennis, Won, Helen, Srinivasan, Preethi, Huberman, Kety, Meng, Fanli, Jing, Xiaohong, Patel, Juber, Hasan, Maysun, Johnson, Ian, Gedvilaite, Erika, Houck-Loomis, Brian, Socci, Nicholas D., Selcuklu, S. Duygu, Seshan, Venkatraman E., Zhang, Hongxin, Chakravarty, Debyani, Zehir, Ahmet, Benayed, Ryma, Arcila, Maria, Ladanyi, Marc, Funt, Samuel A., Feldman, Darren R., Li, Bob T., Razavi, Pedram, Rosenberg, Jonathan, Bajorin, Dean, Iyer, Gopa, Abida, Wassim, Scher, Howard I., Rathkopf, Dana, Viale, Agnes, Berger, Michael F., and Solit, David B.

Published
2021
Full Text
View/download PDF

29. Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness

Author

Hoyos, David, Zappasodi, Roberta, Schulze, Isabell, Sethna, Zachary, de Andrade, Kelvin César, Bajorin, Dean F., Bandlamudi, Chaitanya, Callahan, Margaret K., Funt, Samuel A., Hadrup, Sine R., Holm, Jeppe S., Rosenberg, Jonathan E., Shah, Sohrab P., Vázquez-García, Ignacio, Weigelt, Britta, Wu, Michelle, Zamarin, Dmitriy, Campitelli, Laura F., Osborne, Edward J., Klinger, Mark, Robins, Harlan S., Khincha, Payal P., Savage, Sharon A., Balachandran, Vinod P., Wolchok, Jedd D., Hellmann, Matthew D., Merghoub, Taha, Levine, Arnold J., Łuksza, Marta, and Greenbaum, Benjamin D.

Published
2022
Full Text
View/download PDF

30. Supplemental Tables 1 from Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Author

Guercio, Brendan J., primary, Sarfaty, Michal, primary, Teo, Min Yuen, primary, Ratna, Neha, primary, Duzgol, Cihan, primary, Funt, Samuel A., primary, Lee, Chung-Han, primary, Aggen, David H., primary, Regazzi, Ashley M., primary, Chen, Ziyu, primary, Lattanzi, Michael, primary, Al-Ahmadie, Hikmat A., primary, Brannon, A. Rose, primary, Shah, Ronak, primary, Chu, Carissa, primary, Lenis, Andrew T., primary, Pietzak, Eugene, primary, Bochner, Bernard H., primary, Berger, Michael F., primary, Solit, David B., primary, Rosenberg, Jonathan E., primary, Bajorin, Dean F., primary, and Iyer, Gopa, primary

Published
2023
Full Text
View/download PDF

31. Data from Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Author

Guercio, Brendan J., primary, Sarfaty, Michal, primary, Teo, Min Yuen, primary, Ratna, Neha, primary, Duzgol, Cihan, primary, Funt, Samuel A., primary, Lee, Chung-Han, primary, Aggen, David H., primary, Regazzi, Ashley M., primary, Chen, Ziyu, primary, Lattanzi, Michael, primary, Al-Ahmadie, Hikmat A., primary, Brannon, A. Rose, primary, Shah, Ronak, primary, Chu, Carissa, primary, Lenis, Andrew T., primary, Pietzak, Eugene, primary, Bochner, Bernard H., primary, Berger, Michael F., primary, Solit, David B., primary, Rosenberg, Jonathan E., primary, Bajorin, Dean F., primary, and Iyer, Gopa, primary

Published
2023
Full Text
View/download PDF

32. Supplemental Figures 1 from Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Author

Guercio, Brendan J., primary, Sarfaty, Michal, primary, Teo, Min Yuen, primary, Ratna, Neha, primary, Duzgol, Cihan, primary, Funt, Samuel A., primary, Lee, Chung-Han, primary, Aggen, David H., primary, Regazzi, Ashley M., primary, Chen, Ziyu, primary, Lattanzi, Michael, primary, Al-Ahmadie, Hikmat A., primary, Brannon, A. Rose, primary, Shah, Ronak, primary, Chu, Carissa, primary, Lenis, Andrew T., primary, Pietzak, Eugene, primary, Bochner, Bernard H., primary, Berger, Michael F., primary, Solit, David B., primary, Rosenberg, Jonathan E., primary, Bajorin, Dean F., primary, and Iyer, Gopa, primary

Published
2023
Full Text
View/download PDF

33. Ototoxicity associated with high‐dose carboplatin for patients with previously treated germ cell tumors

Author

Funt, Samuel A., primary, Knezevic, Andrea, additional, Wilson, Kaamilah, additional, Bromberg, Maria, additional, Budnick, Amy, additional, O’Connor, Kerri L., additional, McHugh, Deaglan J., additional, Larsen, Erik, additional, Bajorin, Dean F., additional, Motzer, Robert J., additional, Tonorezos, Emily S., additional, Patil, Sujata, additional, and Feldman, Darren R., additional

Published
2023
Full Text
View/download PDF

35. Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma

Author

Vanguri, Rami S, primary, Smithy, James W, additional, Li, Yanyun, additional, Zhuang, Mingqiang, additional, Maher, Colleen A, additional, Aleynick, Nathaniel, additional, Peng, Xiyu, additional, Al‐Ahmadie, Hikmat, additional, Funt, Samuel A, additional, Rosenberg, Jonathan E, additional, Iyer, Gopa, additional, Bajorin, Dean, additional, Mathews, James C, additional, Nadeem, Saad, additional, Panageas, Katherine S, additional, Shen, Ronglai, additional, Callahan, Margaret K, additional, and Hollmann, Travis J, additional

Published
2023
Full Text
View/download PDF

36. Correction: Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

Author

Teo, Min Yuen, Al-Ahmadie, Hikmat, Seier, Kenneth, Tully, Christopher, Regazzi, Ashley M., Pietzak, Eugene, Solit, David B., Tickoo, Satish, Reuter, Victor, Cha, Eugene K., Herr, Harry, Donahue, Timothy, Donat, Sherri M., Dalbagni, Guido, Bochner, Bernard H., Funt, Samuel, Iyer, Gopakumar V., Bajorin, Dean F., Ostrovnaya, Irina, and Rosenberg, Jonathan E.

Published
2022
Full Text
View/download PDF

38. TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy

Author

Tvingsholm, Siri Amanda, primary, Frej, Marcus Svensson, additional, Rafa, Vibeke Mindahl, additional, Hansen, Ulla Kring, additional, Ormhøj, Maria, additional, Tyron, Alexander, additional, Jensen, Agnete W P, additional, Kadivar, Mohammad, additional, Bentzen, Amalie Kai, additional, Munk, Kamilla K, additional, Aasbjerg, Gitte N, additional, Ternander, Jeppe S H, additional, Heeke, Christina, additional, Tamhane, Tripti, additional, Schmess, Christian, additional, Funt, Samuel A., additional, Kjeldsen, Julie Westerlin, additional, Kverneland, Anders Handrup, additional, Met, Özcan, additional, Draghi, Arianna, additional, Jakobsen, Søren Nyboe, additional, Donia, Marco, additional, Marie Svane, Inge, additional, and Hadrup, Sine Reker, additional

Published
2023
Full Text
View/download PDF

39. Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., primary, Reales, Dalicia, primary, Crowdis, Jett, primary, Noronha, Anne Marie, primary, Wolff, Bernadette, primary, Alano, Tina, primary, Galle, Jesse, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Socci, Nicholas D., primary, Liu, Ying L., primary, Tew, William P., primary, Aghajanian, Carol, primary, Ladanyi, Marc, primary, He, Meng Xiao, primary, AlDubayan, Saud H., primary, Mazor, Roei David, primary, Shpilberg, Ofer, primary, Hershkovitz-Rokah, Oshrat, primary, Riancho, Jose A., primary, Hernandez, Jose L., primary, Gonzalez-Vela, M. Carmen, primary, Buthorn, Justin J., primary, Wilson, Manda, primary, Webber, Amy E., primary, Yabe, Mariko, primary, Petrova-Drus, Kseniya, primary, Rosenblum, Marc, primary, Durham, Benjamin H., primary, Abdel-Wahab, Omar, primary, Berger, Michael F., primary, Donoghue, Mark T.A., primary, Kung, Andrew L., primary, Glade Bender, Julia, primary, Shukla, Neerav N., primary, Funt, Samuel A., primary, Dogan, Ahmet, primary, Soslow, Robert A., primary, Al-Ahmadie, Hikmat, primary, Feldman, Darren R., primary, Van Allen, Eliezer M., primary, Diamond, Eli L., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

40. Data from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., primary, Reales, Dalicia, primary, Crowdis, Jett, primary, Noronha, Anne Marie, primary, Wolff, Bernadette, primary, Alano, Tina, primary, Galle, Jesse, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Socci, Nicholas D., primary, Liu, Ying L., primary, Tew, William P., primary, Aghajanian, Carol, primary, Ladanyi, Marc, primary, He, Meng Xiao, primary, AlDubayan, Saud H., primary, Mazor, Roei David, primary, Shpilberg, Ofer, primary, Hershkovitz-Rokah, Oshrat, primary, Riancho, Jose A., primary, Hernandez, Jose L., primary, Gonzalez-Vela, M. Carmen, primary, Buthorn, Justin J., primary, Wilson, Manda, primary, Webber, Amy E., primary, Yabe, Mariko, primary, Petrova-Drus, Kseniya, primary, Rosenblum, Marc, primary, Durham, Benjamin H., primary, Abdel-Wahab, Omar, primary, Berger, Michael F., primary, Donoghue, Mark T.A., primary, Kung, Andrew L., primary, Glade Bender, Julia, primary, Shukla, Neerav N., primary, Funt, Samuel A., primary, Dogan, Ahmet, primary, Soslow, Robert A., primary, Al-Ahmadie, Hikmat, primary, Feldman, Darren R., primary, Van Allen, Eliezer M., primary, Diamond, Eli L., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., primary, Reales, Dalicia, primary, Crowdis, Jett, primary, Noronha, Anne Marie, primary, Wolff, Bernadette, primary, Alano, Tina, primary, Galle, Jesse, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Socci, Nicholas D., primary, Liu, Ying L., primary, Tew, William P., primary, Aghajanian, Carol, primary, Ladanyi, Marc, primary, He, Meng Xiao, primary, AlDubayan, Saud H., primary, Mazor, Roei David, primary, Shpilberg, Ofer, primary, Hershkovitz-Rokah, Oshrat, primary, Riancho, Jose A., primary, Hernandez, Jose L., primary, Gonzalez-Vela, M. Carmen, primary, Buthorn, Justin J., primary, Wilson, Manda, primary, Webber, Amy E., primary, Yabe, Mariko, primary, Petrova-Drus, Kseniya, primary, Rosenblum, Marc, primary, Durham, Benjamin H., primary, Abdel-Wahab, Omar, primary, Berger, Michael F., primary, Donoghue, Mark T.A., primary, Kung, Andrew L., primary, Glade Bender, Julia, primary, Shukla, Neerav N., primary, Funt, Samuel A., primary, Dogan, Ahmet, primary, Soslow, Robert A., primary, Al-Ahmadie, Hikmat, primary, Feldman, Darren R., primary, Van Allen, Eliezer M., primary, Diamond, Eli L., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

42. Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

Author

Litchfield, Kevin, Reading, James L., Lim, Emilia L., Xu, Hang, Liu, Po, Al-Bakir, Maise, Wong, Yien Ning Sophia, Rowan, Andrew, Funt, Samuel A., Merghoub, Taha, Perkins, David, Lauss, Martin, Svane, Inge Marie, Jönsson, Göran, Herrero, Javier, Larkin, James, Quezada, Sergio A., Hellmann, Matthew D., Turajlic, Samra, and Swanton, Charles

Published
2020
Full Text
View/download PDF

43. Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results.

Author

Sternschuss, Michal, Guercio, Brendan John, Pietzak, Eugene J., Ponomarev, Maria, Regazzi, Ashley M., Quinlan, Colleen, Aggen, David H, Goh, Alvin C., Cha, Eugene K., Donat, S. Machele, Hakimi, A. Ari, Matulewicz, Richard, Funt, Samuel A, Bajorin, Dean F., Iyer, Gopa, Ostrovnaya, Irina, Al-Ahmadie, Hikmat A., Rosenberg, Jonathan E., Coleman, Jonathan, and Teo, Min Yuen

Published
2024
Full Text
View/download PDF

44. HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes.

Author

Shah, Neil J., Aggen, David H, Zheng, Junting, Niederhausern, Andrew, Alam, Syed Muneeb, Balar, Om, Bahadur, Nadia, Watson, Adam, Regazzi, Ashley M., Ratna, Neha, Funt, Samuel A, Teo, Min Yuen, Pietzak, Eugene J., Solit, David B., Bajorin, Dean F., Philip, John, Rosenberg, Jonathan E., Ostrovnaya, Irina, Al-Ahmadie, Hikmat A., and Iyer, Gopa

Published
2024
Full Text
View/download PDF

45. HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer.

Author

Aggen, David H, Shah, Neil J., Zheng, Junting, Alam, Syed Muneeb, Balar, Om, Niederhausern, Andrew, Regazzi, Ashley M., Ratna, Neha, Funt, Samuel A, Teo, Min Yuen, Pietzak, Eugene J., Solit, David B., Bajorin, Dean F., Ostrovnaya, Irina, Rosenberg, Jonathan E., Al-Ahmadie, Hikmat A., and Iyer, Gopa

Published
2024
Full Text
View/download PDF

46. Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma.

Author

Alam, Syed Muneeb, Teo, Min Yuen, Woo, Jun, Sarfaty, Michal, Funt, Samuel A, Aggen, David H, Lee, Chung-Han, Carlo, Marie Isabel, Gandhi, Jatin, Ratna, Neha, Regazzi, Ashley M., Donoghue, Mark, Bajorin, Dean F., Coleman, Jonathan, Rosenberg, Jonathan E., Al-Ahmadie, Hikmat A., Solit, David B., and Iyer, Gopa

Published
2024
Full Text
View/download PDF

48. Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum.

Author

Matulewicz, Richard S., Benfante, Nicole, Funt, Samuel A., Feldman, Darren R., Carver, Brett, Doudt, Alexander, Knezevic, Andrea, Sheinfeld, Joel, Fankhauser, Christian D., Tandstad, Torgrim, Heidenreich, Axel, Passarelli, Rachel, and Jang, Thomas L.

Abstract

Purpose: Primary surgical treatment with retroperitoneal lymph node dissection aims to accurately stage and treat patients with node-positive pure seminoma while avoiding long-term risks of chemotherapy or radiation, traditional standard-of-care treatments. Materials and Methods: We reported the pathologic and oncologic outcomes of patients with pure seminoma treated with primary retroperitoneal lymph node dissection in a retrospective, single-institution case series over 10 years. The primary outcome was 2-year recurrence-free survival stratified by adjuvant management strategy (surveillance vs adjuvant chemotherapy). Results: Forty-five patients treated with primary retroperitoneal lymph node dissection for pure testicular seminoma metastatic to the retroperitoneum were identified. Median size of largest lymph node before surgery was 1.8 cm. Viable germ cell tumor, all of which was pure seminoma, was found in 96% (n[43) of patients. The median number of positive nodes and nodes removed was 2 and 54, respectively. Median positive pathologic node size was 2 cm(IQR 1.4-2.5 cm, range 0.1-5 cm). Four of 29 patients managed with postoperative surveillance experienced relapse; 2-year recurrence-free survival was 81%. Median follow-up for those managed with surveillance who did not relapse was 18.5 months. There were no relapses in the retroperitoneum, visceral recurrences, or deaths. Among the 16 patients who received adjuvant treatment, 1 patient experienced relapse in the pelvis at 19 months. Conclusions: Primary retroperitoneal lymph node dissection for pure seminoma with low-volume metastases to the retroperitoneum is safe and effective, allowing most patients to avoid long-term toxicities from chemotherapy or radiation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies

Author

Reis, Henning, Serrette, Rene, Posada, Jennifer, Lu, Vincent, Chen, Ying-bei, Gopalan, Anuradha, Fine, Samson W., Tickoo, Satish K., Sirintrapun, Sahussapont J., Iyer, Gopa, Funt, Samuel A., Teo, Min Yuen, Rosenberg, Jonathan E., Bajorin, Dean F., Dalbagni, Guido, Bochner, Bernard H., Solit, David B., Reuter, Victor E., and Al-Ahmadie, Hikmat A.

Published
2019
Full Text
View/download PDF

50. PD09-07 ASSESSING THE UTILITY OF A CELL-FREE TUMOR (ct)DNA ASSAY (MSK-ACCESS) IN NODE POSITIVE (N+) MUSCLE INVASIVE BLADDER CANCER (MIBC) PATIENTS (pts) UNDERGOING NEOADJUVANT CHEMOTHERAPY (NAC)

Author

Katims, Andrew B., primary, Lenis, Andrew T., additional, Shah, Ronak H., additional, Chu, Carissa E., additional, Ratna, Neha, additional, Regazzi, Ashely M., additional, Pietzak, Eugene J., additional, Aggen, David H., additional, Funt, Samuel A., additional, Teo, Min Yuen, additional, Rosenberg, Jonathan E., additional, Bajorin, Dean F., additional, Donahue, Timothy F., additional, Bochner, Bernard H., additional, Berger, Michael F., additional, Solit, David B., additional, and Iyer, Gopa, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results